Researchers Document Longest Known COVID-19 Infection, Occult InfectionApril 27th 2022
Lasting 505 days, investigators documented the longest known COVID-19 infection. The research, presented at ECCMID, also found one of the first cases of occult COVID-19, in which a patient who tests negative is later found to have ongoing COVID-19.
Novel Antibiotics for Resistant Pathogens: Results of ATTACK Trial for Sulbactam-DurlobactamApril 26th 2022
Entasis Therapeutics gave 2 oral presentations at ECCMID today detailing results of their ATTACK trial, investigating the safety and efficacy of sulbactam-durlobactam (SUL-DUR) for multidrug-resistant pathogens.
Longer Intervals Between COVID-19 Vaccine Doses Leads to Higher Antibody LevelsApril 25th 2022
One study, presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), found waiting longer in between the first and second Pfizer-BioNTech vaccine doses boosted immune response 9-fold.
Shionogi’s Oral Antiviral S-217622 Rapidly Clears COVID-19 VirusApril 23rd 2022
Today at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), Shionogi presented late-breaking data from their phase 2/3 clinical trial for S-217622, an investigational 3CL protease inhibitor. On day 4 of treatment with Shionogi’s S-217622, COVID-19 positive viral titers decreased by 90%.
Testing Procalcitonin Levels to Guide Antimicrobial StewardshipApril 21st 2022
Investigators used procalcitonin (PCT) levels to guide antibiotic recommendations in pediatric intensive care units. PCT-guided antibiotic stewardship decreased the number of antibiotic days without leading to therapy failure.
Identifying High-Risk Recurrent Clostridioides Difficile Patients for BezlotoxumabApril 18th 2022
The greatest risk factors for recurrent Clostridioides difficile infection (CDI) were age of at least 65 years, severe primary CDI, and use of non-CDI antibiotics. Patients with these risk factors should be prioritized for bezlotoxumab therapy.
Fidaxomicin Versus Vancomycin for Clostridioides Difficile TreatmentApril 15th 2022
Concomitant antibiotic (CA) use for infection treatment is a major risk factor for recurrent C difficile infection. One SHEA 2022 study examined whether fidaxomicin or vancomycin would be more beneficial for CA patients.
COVID-19 Risk Factors, Broken Down by OccupationApril 13th 2022
An examination of COVID-19 infections by occupation found that most cases occurred in people who worked in management and healthcare, and COVID-19 death rates were highest among building/grounds cleaning and maintenance employees.